Nanoformulations of Herbal Extracts in Treatment of Neurodegenerative Disorders
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Nanotechnology is one of the methods that have been able to influence human life in different ways and is a substantial tool that assists to overcome the multiple limitations in the treatment of various diseases, especially neurodegenerative disorders (NDs). Various nanostructures such as polymer nanoparticles, lipid nanoparticles, nanoliposomes, nano-micelle, carbon nanotubes (CNTs), besides different vehicle systems including poly lactic-co-glycolic acid, lactoferrin, polybutylcyanoacrylate and some others significantly increased the effectiveness, reduced the side effects, enhanced the stability, and improved the pharmacokinetics of several drugs. NDs belong to a group of annoying and debilitating disorders involving millions of people worldwide. Privious studies revealed that several nano formulations from a number of natural products such as curcumin (Cur), quercetin (QC), resveratrol (RSV), piperine (PIP), Ginkgo biloba, and Nigella sativa showed significant effectiveness in improving the condition of patients with NDs. The blood-brain barrier (BBB) is the main limitation of NDs management. In this review, we have attempted to discuss the effects of herbal-based nano formulation that used to treat such diseases. In summary, herbal-based nanoformulations seem to be significant in the treatment of NDs, alone or in combination with other drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Aberrant accumulation of Lewy bodies is also reported in PD patients (Braak et al., 2003; Del Tredici and Braak, 2012).”
BackgroundDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
The physiology, signaling, and pharmacology of dopamine receptors
Beaulieu, J.-M., & Gainetdinov, R. R. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.002642 · Cited by 2,763
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Oligodendroglia metabolically support axons and contribute to neurodegeneration
Lee, Y., Morrison, B. M., Li, Y., Lengacher, S., Farah, M. H., Hoffman, P. N., Liu, Y., Tsingalia, A., Jin, L., Zhang, P.-W., et al. (2012) · Nature · doi:10.1038/nature11314 · Cited by 1,664
Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.5 · Cited by 1,641
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity
Fünfschilling, U., Supplie, L. M., Mahad, D., Boretius, S., Saab, A. S., Edgar, J., Brinkmann, B. G., Kassmann, C. M., Tzvetanova, I. D., Möbius, W., et al. (2012) · Nature · doi:10.1038/nature11007 · Cited by 1,523
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016
Tai chi and postural stability in patients with Parkinson's disease
Li, F., Harmer, P., Fitzgerald, K., Eckstrom, E., Stock, R., Galver, J., Maddalozzo, G., & Batya, S. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107911 · Cited by 890
Price, J. L., Davis, P. B., Morris, J. C., & White, D. L. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90006-6 · Cited by 818
Incidence of amyotrophic lateral sclerosis in Europe
Logroscino, G., Traynor, B. J., Hardiman, O., Chio, A., Mitchell, D., Swingler, R. J., Millul, A., Benn, E., Beghi, E., & EURALS, F. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.183525 · Cited by 772
Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study
Schrag, A., Horsfall, L., Walters, K., Noyce, A., & Petersen, I. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70287-x · Cited by 674
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Nanomaterial-based blood-brain-barrier (BBB) crossing strategies
Xie, J., Shen, Z., Anraku, Y., Kataoka, K., & Chen, X. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119491 · Cited by 604
Tiwari, S. K., Agarwal, S., Seth, B., Yadav, A., Nair, S., Bhatnagar, P., Karmakar, M., Kumari, M., Chauhan, L. K. S., Patel, D. K., et al. (2014) · ACS Nano · doi:10.1021/nn405077y · Cited by 558
Neuroprotective Mechanisms of Resveratrol in Alzheimer’s Disease: Role of SIRT1
Gomes, B. A. Q., Silva, J. P. B., Romeiro, C. F. R., dos Santos, S. M., Rodrigues, C. A., Gonçalves, P. R., Sakai, J. T., Mendes, P. F. S., Varela, E. L. P., & Monteiro, M. C. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/8152373 · Cited by 403
Smith, A., Giunta, B., Bickford, P. C., Fountain, M., Tan, J., & Shytle, R. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.01.012 · Cited by 280
Mourtas, S., Lazar, A. N., Markoutsa, E., Duyckaerts, C., & Antimisiaris, S. G. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.050 · Cited by 263
Sandhir, R., Yadav, A., Mehrotra, A., Sunkaria, A., Singh, A., & Sharma, S. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8261-y · Cited by 204
Pangeni, R., Sharma, S., Mustafa, G., Ali, J., & Baboota, S. (2014) · Nanotechnology · doi:10.1088/0957-4484/25/48/485102 · Cited by 192
Formulations of Curcumin Nanoparticles for Brain Diseases
Del Prado-Audelo, M. L., Caballero-Florán, I. H., Meza-Toledo, J. A., Mendoza-Muñoz, N., González-Torres, M., Florán, B., Cortés, H., & Leyva-Gómez, G. (2019) · Biomolecules · doi:10.3390/biom9020056 · Cited by 191
Clinical development of curcumin in neurodegenerative disease
Hu, S., Maiti, P., Ma, Q., Zuo, X., Jones, M. R., Cole, G. M., & Frautschy, S. A. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1044981 · Cited by 179
Meng, F., Asghar, S., Gao, S., Su, Z., Song, J., Huo, M., Meng, W., Ping, Q., & Xiao, Y. (2015) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2015.06.025 · Cited by 176
Frozza, R. L., Bernardi, A., Hoppe, J. B., Meneghetti, A. B., Matté, A., Battastini, A. M. O., Pohlmann, A. R., Guterres, S. S., & Salbego, C. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8401-2 · Cited by 165 · cited 2×
“An optimized RSV-loaded lipid-core NPs (RSVLNC) modulated the Aβ-triggered neuroinflammation in vitro (Frozza et al., 2013a).”
BackgroundMethodTheranostic applications of nanoparticles in neurodegenerative disorders
Ramanathan, S., Archunan, G., Sivakumar, M., Tamil Selvan, S., Fred, A. L., Kumar, S., Gulyás, B., & Padmanabhan, P. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s149022 · Cited by 161
Taylor, M., Moore, S., Mourtas, S., Niarakis, A., Re, F., Zona, C., Ferla, B. L., Nicotra, F., Masserini, M., Antimisiaris, S. G., et al. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.06.015 · Cited by 149
Esteves, M., Cristóvão, A. C., Saraiva, T., Rocha, S. M., Baltazar, G., Ferreira, L., & Bernardino, L. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00020 · Cited by 88
He, X., Yang, S., Zhang, R., Hou, L., Xu, J., Hu, Y., Xu, R., Wang, H., & Zhang, Y. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00018 · Cited by 27
Cited by
Neuroprotective Strategies for Neurological Disorders by Natural Products: An update
Rehman, M. U., Wali, A. F., Ahmad, A., Shakeel, S., Rasool, S., Ali, R., Rashid, S. M., Madkhali, H., Ganaie, M. A., & Khan, R. (2019) · Current Neuropharmacology · doi:10.2174/1570159x16666180911124605 · Cited by 265
Rahimifard, M., Baeeri, M., Bahadar, H., Moini-Nodeh, S., Khalid, M., Haghi-Aminjan, H., Mohammadian, H., & Abdollahi, M. (2020) · Molecules · doi:10.3390/molecules25245875 · Cited by 61
Self-citationRetractedRodrigues, R. O., Shin, S.-R., & Bañobre-López, M. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02720-0 · Cited by 44
“Among them are curcumin, quercetin, resveratrol, piperine, Omega 3, Ginkgo biloba and Nigella sativa [80], which typically shows anti-inflammatory, antioxidant, [47, 90–92] antiproliferative and antiangiogenic activities.”
Background
Metadata
- Authors
- Moradi, S. Z., Momtaz, S., Bayrami, Z., Farzaei, M. H., & Abdollahi, M.
- Venue
- Frontiers in Bioengineering and Biotechnology
- Publisher
- Frontiers Media SA
- Published
- 2020-04-07
- Volume
- 8
- Pages
- 238-238
- ISSN
- 2296-4185 (ISSN-L)
- OpenAlex
- W3015599023
- Cited by
- 180
- References
- 30
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.